From CGMPs to the Critical Path: FDA Focuses on Innovation, Quality, and Continuous Improvement–Inside and Out
By Laura Bush
News
Article
Pharmaceutical TechnologyPharmaceutical Technology-07-02-2004
Volume 28
Issue 7
As FDA prepares for the Critical Path initiative, offices across the agency are expanding the use of the risk-based approach to regulation and applying a quality systems approach to internal operations.
Articles in this issue
3M Drug Delivery Systems
AccuRate
July 2004
Characterization of the Performance of Bin Blenders Part 2 of 3: Free-Flowing Mixtures
Investors Shy Away from Pharmaceutical Chemicals
From CGMPs to the Critical Path: FDA Focuses on Innovation, Quality, and Continuous Improvement–Inside and Out
In the Spotlight-July 2004
The LR Method in Critical Areas: Airflow Patterns and the Design of Aseptic Interventions
A Stability Program for the Distribution of Drug Products
Politics Versus Science in Biomedical Research and Development
Recent Videos
Related Content
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025Article
With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.
